Gene therapy for high-grade glioma

Neurologia Medico-Chirurgica

Volumn 50, Issue 9, 2010, Pages 727-736

  Iwami, Ken Ichiro ^a   Natsume, Atsushi ^a   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical trial; Gene therapy; Glioma

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; BETA INTERFERON; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2; INTERLEUKIN 4; LENTIVIRUS VECTOR; LIPOSOME; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOPHENOL MONOOXYGENASE; NAKED DNA; ONCOLYTIC VIRUS; ONYX 015; PLASMID DNA; PROTEIN P53; RETROVIRUS VECTOR; SMALL INTERFERING RNA; SOMATOMEDIN C; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VALACICLOVIR;

ADENOVIRUS; ANTISENSE THERAPY; ARTICLE; CANCER GRADING; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA MODIFICATION; GENE THERAPY; GENETIC ENGINEERING; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; LYMPHOCYTE TRANSFER; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; POLIOMYELITIS VIRUS; PROGNOSIS; SEMLIKI FOREST ALPHAVIRUS; SUICIDE GENE THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

BRAIN NEOPLASMS; GENETIC THERAPY; GENETIC VECTORS; GLIOMA; HUMANS;

EID: 77958110297     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.50.727     Document Type: Article

References (87)

1. Aghi MK, Chiocca EA: Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 17: 8-9, 2009
2. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M: Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 50: 215-222, 1992
3. Barba D, Hardin J, Sadelain M, Gage FH: Develop-ment of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91: 4348-4352,1994
4. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323, 1997
5. Borden EC, Lindner D, Dreicer R, Hussein M, Peere-boom D: Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 10: 125-144, 2000
6. Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, Todorov I, Shih CC, Badie B, Hudecek M, Riddell SR, Jensen MC: Recognition and killing of brain tumor stem-like initiating cells by CD8 + cytolytic T cells. Cancer Res 69: 8886-8893, 2009
7. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, Downie P, Hassall TE, Tang ML, Ashley DM: Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6: 236-246, 2004
8. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C: NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182: 3530-3539, 2009
9. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A: Gene therapy of human severe combined immunodeficiency (SCID'-X1 disease. Science 288: 669-672, 2000
10. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J: A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovi-rus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10: 958-966, 2004
11. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D: A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16: 618-626, 2008
12. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992
13. Fehse B, Roeder I: Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther 15: 143-153, 2008
14. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987
15. Fick J, Barker FG 2nd, Dazin P, Westphale EM, Beyer EC, Israel MA: The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 92: 11071-11075, 1995
16. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis ele-gans. Nature 391: 806-811, 1998
17. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The bystander effect'': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993
18. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E: Retroviral vector-mediated gamma-inter-feron gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820-7825, 1990
19. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990
20. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G: Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015' in human malignant glioma xenografts. Br J Cancer 89: 577-584, 2003
21. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G: Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62: 764-772, 2002
22. Gromeier M, Alexander L, Wimmer E: Internal ribosomal entry site substitution eliminates neu-rovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA 93: 2370-2375, 1996
23. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97: 6803-6808, 2000
24. Hartman ZC, Appledorn DM, Amalfitano A: Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132: 1-14, 2008
25. Horst M, Brouwer E, Verwijnen S, Rodijk M, de Jong M, Hoeben R, de Leeuw B, Smitt PS: Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP'-selective oncolytic adenovirus. J Gene Med9: 1071-1079, 2007
26. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol73: 6319-6326, 1999
27. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59: 895-900, 1999
28. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, For-man SJ, Jensen MC: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9166, 2004
29. Kim JH, Kim SH, Kolozsvary A, Brown SL, Kim OB, Freytag SO: Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 33: 861-868, 1995
30. Kim SH, Kim S, Robbins PD: Retroviral vectors. Adv Virus Res 55: 545-563, 2000
31. Kim SK, Cargioli TG, Machluf M, Yang W, Sun Y, Al-Hashem R, Kim SU, Black PM, Carroll RS: PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res 11: 5965-5970, 2005
32. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. JNeu-ropathol Exp Neurol 61: 215-225, 2002
33. Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glio-ma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004
34. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5: 637-642, 1999
35. Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786, 2001
36. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207, 2009
37. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tor-natore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874, 2000
38. Matthews T, Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10 Suppl 3: S490-S494, 1988
39. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M: Poliovirus receptor CDl55-targeted oncolysis of glioma. Neuro Oncol 6: 208-217, 2004
40. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994
41. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex vi-rus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943, 1995
42. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest106: 1065-1069, 2000
43. Mizuno M, Yoshida J: Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother 47: 227-232, 1998
44. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986
45. Natsume A, Mizuno M, Ryuke Y, Yoshida J: An-titumor effect and cellular immunity activation by murine interferon-beta gene transfer against in-tracerebral glioma in mouse. Gene Ther 6: 1626-1633, 1999
46. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J: IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neu-rooncol 47: 117-124, 2000
47. Nestler U, Wakimoto H, Siller-Lopez F, Aguilar LK, Chakravarti A, Muzikansky A, Stemmer-Rachamimov A, Chiocca EA, Aguilar-Cordova E, Hochberg FH: The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol 67: 177-188, 2004
48. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kon-dziolka D, Lieberman F, Schiff D, Attanucci J, Edin-gton H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E: Gene therapy of malignant glio-mas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 11: 637-653, 2000
49. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, Harland J, Mabbs R, Brown M: The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following in-tratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398-406, 2002
50. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z, Van Meir EG: Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 10: 8603-8612, 2004
51. Puri RK, Leland P, Kreitman RJ, Pastan I: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58: 574-581, 1994
52. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and gan-ciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389-2401, 2000
53. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83-88, 1993
54. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vas-culature and growth of 9L gliomas in rats. J Neu-rosurg 81: 256-260, 1994
55. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866, 2000
56. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54: 2218-2222, 1994
57. Roth JA: Adenovirus p53 gene therapy. Expert Opin Biol Ther 6: 55-61, 2006
58. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carras-co CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nes-bitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopad-hyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985-991, 1996
59. Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, Bauters F, Fenaux P, Quesnel B: Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 16: 1637-1644, 2002
60. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S: Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 177: 137-150, 2008
61. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004
62. Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG: CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 65: 10930-10937, 2005
63. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA, Royston I: Interleukin-2 gene therapy in a patient with gliob-lastoma. Gene Ther 2: 164-167, 1995
64. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998
65. Streck CJ, Dickson PV, Ng CY, Zhou J, Hall MM, Gray JT, Nathwani AC, Davidoff AM: Antitumor efficacy of AAV-mediated systemic delivery of inter-feron-beta. Cancer Gene Ther 13: 99-106, 2006
66. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A: Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotox-ic T lymphocytes. Gene Ther 7: 2028-2035, 2000
67. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Engl J Med352: 987-996, 2005
68. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 74: 3832-3841, 2000
69. Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, King MC, Johnson DH, Holt JT: A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 3: 1959-1968, 1997
70. Tiberghien P: Use of suicide genes in gene therapy. J Leukoc Biol 56: 203-209, 1994
71. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and inter-feron-gamma. Cancer Res 55: 1902-1910, 1995
72. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97: 14720-14725, 2000
73. Uren AG, Kool J, Berns A, van Lohuizen M: Retroviral insertional mutagenesis: past, present and future. Oncogene 24: 7656-7672, 2005
74. Vallieres L: Trabedersen, a TGFbeta2-specific an-tisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2. IDrugs 12: 445-453, 2009
75. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98: 49-56, 2001
76. Verma IM, Somia N: Gene therapy-promises, problems and prospects. Nature 389: 239-242, 1997
77. Vousden KH, Lane DP: P53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007
78. Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J: A phase I clinical trial of inter-feron-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med 10: 329-339, 2008
79. Wei MX, Tamiya T, Hurford RK Jr, Boviatsis EJ, Tep-per RI, Chiocca EA: Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 6: 437-443, 1995
80. Weller M, Fontana A: The failure of current im-munotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 21: 128-151, 1995
81. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319, 1993
82. Wojtowicz-Praga S: Reversal of tumor-induced im-munosuppression: a new approach to cancer therapy. J Immunother 20: 165-177, 1997
83. Yagi K, Hayashi Y, Ishida N, Ohbayashi M, Ohishi N, Mizuno M, Yoshida J: Interferon-beta endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: cytocidal effect on glio-ma transplanted into nude mouse brain. Biochem Mol Biol Int 32: 167-171, 1994
84. Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, Saito R, Nobayashi M, Wakabayashi T: Human gene therapy for malignant gliomas (gliob-lastoma multiforme and anaplastic astrocytoma' by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15: 77-86, 2004
85. Young LS, Searle PF, Onion D, Mautner V: Viral gene therapy strategies: from basic science to clinical application. JPathol208: 299-318, 2006
86. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI:Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 53: 3125-3128, 1993
87. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS: Isolation of cancer stem cells from adult glioblastoma mul-tiforme. Oncogene 23: 9392-9400, 2004